Suppr超能文献

探究 N-取代吖啶酮对微管亲和调节激酶 4 的抑制作用。

Probing the Inhibition of Microtubule Affinity Regulating Kinase 4 by N-Substituted Acridones.

机构信息

Department of Chemistry, Aristotle University of Thessaloniki, University Campus, 54124, Thessaloniki, Greece.

Centre for interdisciplinary research in Basic Sciences, Jamia Millia Islamia, Jamia Nagar, New Delhi, 110025, India.

出版信息

Sci Rep. 2019 Feb 8;9(1):1676. doi: 10.1038/s41598-018-38217-8.

Abstract

Microtubule affinity regulating kinase 4 (MARK4) becomes a unique anti-cancer drug target as its overexpression is responsible for different types of cancers. In quest of novel, effective MARK4 inhibitors, some acridone derivatives were synthesized, characterized and evaluated for inhibitory activity against human MARK4. Among all the synthesized compounds, three (7b, 7d and 7f) were found to have better binding affinity and enzyme inhibition activity in µM range as shown by fluorescence binding, ITC and kinase assays. Here we used functional assays of selected potential lead molecules with commercially available panel of 26 kinases of same family. A distinctive kinase selectivity profile was observed for each compound. The selective compounds were identified with submicromolar cellular activity against MARK4. Furthermore, in vitro antitumor evaluation against cancerous cells (MCF-7 and HepG2) revealed that compounds 7b, 7d and 7f inhibit cell proliferation and predominantly induce apoptosis in MCF-7 cells, with IC values of 5.2 ± 1.2 μM, 6.3 ± 1.2 μM, and 5.8 ± 1.4 μM respectively. In addition, these compounds significantly upsurge the oxidative stress in cancerous cells. Our observations support our approach for the synthesis of effective inhibitors against MARK4 that can be taken forward for the development of novel anticancer molecules targeting MARK4.

摘要

微管亲和调节激酶 4(MARK4)成为一种独特的抗癌药物靶点,因为其过表达与多种类型的癌症有关。为了寻找新型有效的 MARK4 抑制剂,我们合成了一些吖啶酮衍生物,并对其抑制人 MARK4 的活性进行了评价。在所合成的化合物中,有三种(7b、7d 和 7f)在荧光结合、ITC 和激酶测定中显示出更好的结合亲和力和酶抑制活性,在µM 范围内。在这里,我们使用具有商业可用性的相同家族的 26 种激酶的面板,对选定的潜在先导分子进行了功能测定。每种化合物都表现出独特的激酶选择性特征。具有亚微摩尔细胞对 MARK4 活性的选择性化合物被鉴定出来。此外,对癌细胞(MCF-7 和 HepG2)的体外抗肿瘤评估表明,化合物 7b、7d 和 7f 抑制细胞增殖,并在 MCF-7 细胞中主要诱导细胞凋亡,IC 值分别为 5.2±1.2μM、6.3±1.2μM 和 5.8±1.4μM。此外,这些化合物显著增加了癌细胞中的氧化应激。我们的观察结果支持我们合成针对 MARK4 的有效抑制剂的方法,这些抑制剂可以进一步开发针对 MARK4 的新型抗癌分子。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77f5/6368574/0242042960dc/41598_2018_38217_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验